Matrix metalloproteinase 16 (MMP16)

Matrix metalloproteinase 16 (MMP16), also known as MT3-MMP, is a membrane-bound enzyme belonging to the matrix metalloproteinase family that plays a critical role in the degradation of extracellular matrix (ECM) components such as collagen type III and fibronectin [1, 2]. Beyond direct ECM proteolysis, a primary biological function of MMP16 is the activation of progelatinase A (proMMP2), which facilitates further matrix remodeling and promotes cellular processes like angiogenesis and tissue development [3, 11]. In pathological contexts, MMP16 is frequently overexpressed in various malignancies, including melanoma, gastric cancer, and hepatocellular carcinoma, where it drives epithelial-mesenchymal transition (EMT), tumor cell invasion, and metastasis [8, 13, 18]. Due to its significant role in cancer progression and poor patient prognosis, it is considered a viable therapeutic target [15, 19]. Historically, drug development has focused on broad-spectrum matrix metalloproteinase inhibitors (MMPIs) like Marimastat and Batimastat, which target the catalytic zinc ion; however, these often failed in clinical trials due to a lack of specificity and the development of musculoskeletal syndrome [17, 21]. Current research efforts are directed toward developing highly selective inhibitors, such as monoclonal antibodies or exosite-binding small molecules, to minimize off-target toxicities while effectively blocking MMP16-mediated tumor invasion [21, 23].

Other names

MMP-16MT3-MMPMT3MMPMMP-X2Membrane-type matrix metalloproteinase 3Membrane-type-3 matrix metalloproteinaseMatrix metallopeptidase 16

Inhibition of the catalytic zinc-binding site, allosteric blocking of the active site, or prevention of proMMP activation to inhibit proteolytic activity.